02.16.24 -- 4 Focus Areas To Improve AAV Production Lines

Review four key factors for improving on-time delivery when outsourcing drug product manufacturing and discover how investing in building a solid relationship with your CDMO improves timelines.

The key to navigating the biologic development journey lies in CMC. By analyzing and characterizing the drug's properties, CMC teams ensure a smooth path from bench to patient care.

To keep up with oligonucleotide demand, manufacturing needs to shift toward larger-scale processes, but this up-scaling process brings challenges that must be addressed.

An overview of the trend of multiproduct and flexible facilities, defining the different types of facilities, and how working with a partner is a strategic move for any company.

Common resin-based purification and Protein A membrane purification methods have distinct differences in terms of specificity, selectivity, purity, yield, cost, and time required.

Explore a demonstration of a 250 mL bioreactor system designed to run off-site in the cloud, as well as the results of its use in both cell culture and fermentation applications.

This guide explores the use of viral vectors in gene therapies, as well as fluid management and other factors that negatively affect viral vectors during manufacturing.

Find out how a global biotechnology manufacturing company executing several interrelated projects achieved critical project objectives while adhering to schedule and financial commitments.

Unlocking the full potential of viral vector-based therapies requires an understanding of existing challenges in viral vector production and what technologies are now available to help address them.

Many companies are turning to CDMOs to optimize biomanufacturing processes and address the growing list of complications on the path to commercialization.

Learn how ADCs are built, which considerations are critical for their engineering, and how that impacts their stability characteristics.

While more biotech companies are entering the market, advanced therapy startups can still benefit from product and service options that help address challenges in the MSC or EV/exosome space.

Review the pros and cons of soluble and insoluble processes, experiences with isolating, solubilizing, and properly refolding, and strategies and innovation to improve insoluble processes.